Clinical Trial Update: Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating Infigratinib in combination with Tamoxifen for hormone receptor-positive, HER2-negative FGFR-altered advanced breast cancer was termi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Infigratinib (infigratinib)
• Tamoxifen (tamoxifen)

Snippet

Sponsor: Jennifer Lee Caswell-Jin | Conditions: Breast Cancer, HER2-negative Breast Cancer | Phase 1 | Status: TERMINATED | Results posted: 2023-06-01